Workflow
半年度报告
icon
Search documents
贝斯美: 2025年半年度报告摘要
Zheng Quan Zhi Xing· 2025-08-19 16:22
Company Overview - Shaoxing BSM Chemical Co., Ltd. reported a revenue of CNY 776.13 million for the first half of 2025, representing a 16.57% increase compared to CNY 665.83 million in the same period last year [1] - The net profit attributable to shareholders increased by 109.70% to CNY 34.71 million from CNY 16.55 million year-on-year [1] - Basic and diluted earnings per share both doubled to CNY 0.10 from CNY 0.05 [1] Financial Performance - The company experienced a significant decline in net cash flow from operating activities, which was negative CNY 22.33 million, down 162.44% from CNY 35.76 million in the previous year [1] - The total assets at the end of the reporting period were CNY 3.26 billion, a 3.04% increase from CNY 3.16 billion at the end of the previous year [2] - The net assets attributable to shareholders rose to CNY 1.73 billion, reflecting a 1.02% increase from CNY 1.71 billion [2] Shareholder Information - The largest shareholder, Ningbo BSM Investment Holdings Co., Ltd., holds 23.02% of the shares, with 41.33 million shares pledged [3] - Other significant shareholders include Jiangsu Xihua Private Equity Fund Management Co., Ltd. with 5.35% and Wang Qifeng with 3.38% [3] - The report indicates that there were no changes in the controlling shareholder or actual controller during the reporting period [4]
菲菱科思: 董事会决议公告
Zheng Quan Zhi Xing· 2025-08-19 16:22
本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有 虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 深圳市菲菱科思通信技术股份有限公司(以下简称"公司")第四届董事会 第四次会议通知于 2025 年 8 月 8 日以电子邮件方式送达至全体董事,会议定于 次会议由公司董事长陈龙发先生召集并主持,会议应出席董事 5 名,实际出席 会议的董事 5 名,其中以通讯表决方式出席会议的董事人数 3 名,为独立董事 夏永先生及游林儒先生、董事储昭立先生。公司高级管理人员列席了本次会议。 会议的召集、召开、表决程序符合《中华人民共和国公司法》(以下简称"《公 司法》")等法律、行政法规、部门规章、规范性文件和《深圳市菲菱科思通信 技术股份有限公司章程》(以下简称"《公司章程》")的有关规定。 二、董事会会议审议情况 证券代码:301191 证券简称:菲菱科思 公告编号:2025-057 深圳市菲菱科思通信技术股份有限公司 第四届董事会第四次会议决议公告 董事会认为:公司募集资金的存放、管理与使用情况符合《上市公司募集 资金监管规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市 公司规范运 ...
众合科技: 2025年半年度报告摘要
Zheng Quan Zhi Xing· 2025-08-19 11:12
| | | | | 本报告期末 | | | 上年度末 | | 末增减 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 总资产(元) | | | | 9,121,819,403.63 | | | | | | | | 9,321,828,929.45 | | | -2.15% | | | | | | | | | 归属于上市公司股东的净资产(元) | | | | | | 3,302,034,751.45 | | | | | | 3,410,606,939.56 | | | -3.18% | | | | | | | | | | | | | | | | | | | 单位: | | 股 | | | | | | | | | | | | 报告期末普通股股东总 | | | | | | 报告期末表决权恢复的优先股股东总 | | | | | | 数 | | | | 数(如有) | | | | | | | | | 前 | 10 | | | 名股东持股情况(不含通过转融通出借股份) | | | | | | | | | | | | | 持 ...
普洛药业: 2025年半年度报告摘要
Zheng Quan Zhi Xing· 2025-08-19 10:13
Core Viewpoint - The report highlights a decline in revenue and net profit for the first half of 2025 compared to the same period in 2024, indicating potential challenges in the company's financial performance [2][3]. Financial Performance - Operating revenue for the first half of 2025 was approximately 5.44 billion yuan, a decrease of 15.31% from 6.43 billion yuan in the same period last year [2][3]. - Net profit attributable to shareholders was about 563 million yuan, down 9.89% from 625 million yuan in the previous year [2][3]. - The net profit after deducting non-recurring gains and losses was not specified but indicates a decline in overall profitability [2]. - The net cash flow from operating activities was approximately 407 million yuan, reflecting a significant drop of 58.48% from nearly 981 million yuan in the previous year [2][3]. - Basic earnings per share were 0.4861 yuan, a decrease of 9.14% from 0.5350 yuan [3]. Asset and Equity Position - Total assets at the end of the reporting period were approximately 12.48 billion yuan, down 1.93% from 12.73 billion yuan at the end of the previous year [3]. - Net assets attributable to shareholders were about 6.75 billion yuan, showing a slight increase of 0.10% from 6.74 billion yuan [3]. Shareholder Information - The largest shareholder, Hongdian Group, holds 28.57% of the shares, amounting to approximately 330.94 million shares [3]. - Other significant shareholders include Zhejiang Hongdian Import and Export Co., Ltd. with 13.51% and Zhejiang Hongrun Technology Co., Ltd. with 5.15% [3]. Important Matters - There were no significant matters reported during the period [5].
佛燃能源: 2025年半年度报告摘要
Zheng Quan Zhi Xing· 2025-08-19 09:14
佛燃能源集团股份有限公司 2025 年半年度报 告摘要 证券代码:002911 证券简称:佛燃能源 公告编 号:2025-066 佛燃能源集团股份有限公司 本公司及董事会全体成员保证公告内容的真实、准确和完整,没有虚假记载、误导性 陈述或重大遗漏。 一、重要提示 本半年度报告摘要来自半年度报告全文,为全面了解本公司的经营成果、财务状况及未来发展规划,投 资者应当到证监 会指定媒体仔细阅读半年度报告全文。 所有董事均已出席了审议本报告的董事会会议。 非标准审计意见提示 □适用 ?不适用 董事会审议的报告期利润分配预案或公积金转增股本预案 □适用 ?不适用 公司计划不派发现金红利,不送红股,不以公积金转增股本。 董事会决议通过的本报告期优先股利润分配预案 □适用 ?不适用 二、公司基本情况 股票简称 佛燃能源 股票代码 002911 股票上市交易所 深圳证券交易所 变更前的股票简称(如有) 佛燃股份 联系人和联系方式 董事会秘书 证券事务代 表 姓名 卢志刚 李瑛 办公地址 佛山市禅城区南海大道中 18 号 佛山市禅城区南海大 道中 18 号 电话 0757-83036288 0757-83036288 电子信箱 ...
热威股份: 第二届董事会第二十五次会议决议公告
Zheng Quan Zhi Xing· 2025-08-18 16:18
Group 1 - The company held its 25th meeting of the second board on August 18, 2025, with all 7 directors present, confirming compliance with legal and regulatory requirements [1] - The board approved the 2025 semi-annual report, affirming that it accurately reflects the company's financial status and operational results without any misleading statements or omissions [2][3] - The board also approved the special report on the storage and actual use of raised funds, confirming compliance with relevant laws and regulations [2][3] Group 2 - The board approved the expected daily related transactions for 2025, stating that the decision-making process is legal and does not harm the interests of the company or its shareholders [3] - The board authorized the opening of special accounts for raised funds to enhance the efficiency of fund usage and maintain investor rights, with all 7 votes in favor [4]
紫光国微(002049.SZ):上半年实现营收30.47亿元 同比增长6.07%
Ge Long Hui A P P· 2025-08-18 12:56
Core Viewpoint - Unisplendour Corporation Limited (002049.SZ) reported a revenue of 3.047 billion yuan for the first half of 2025, reflecting a year-on-year growth of 6.07% while the net profit attributable to shareholders decreased by 6.18% to 692 million yuan due to reduced non-recurring gains from equity disposals and government subsidies [1] Financial Performance - The company's operating revenue for the first half of 2025 was 3.047 billion yuan, which is a 6.07% increase compared to the same period last year [1] - The net profit attributable to shareholders was 692 million yuan, showing a decline of 6.18% year-on-year, primarily due to a decrease in non-recurring gains [1] - The net profit attributable to shareholders after deducting non-recurring gains was 653 million yuan, representing a year-on-year growth of 4.39% [1] - Basic earnings per share were reported at 0.8206 yuan [1]
海兴电力(603556.SH):上半年净利润3.96亿元,同比下降25.74%
Ge Long Hui A P P· 2025-08-18 12:45
格隆汇8月18日丨海兴电力(603556.SH)公布2025年半年度报告,报告期实现营业收入19.24亿元,同比下 降14.67%;归属于上市公司股东的净利润3.96亿元,同比下降25.74%;归属于上市公司股东的扣除非经 常性损益的净利润3.76亿元,同比下降28.09%;基本每股收益0.82元。 报告期内,公司利润总额同比下降的主要原因系部分国内项目履约推迟、个别海外国家需求波动导致收 入下滑以及公司主动增加逆周期投入导致费用增长所致。 ...
兴福电子: 湖北兴福电子材料股份有限公司2025年半年度报告摘要
Zheng Quan Zhi Xing· 2025-08-18 12:09
湖北兴福电子材料股份有限公司2025 年半年度报告摘要 公司代码:688545 公司简称:兴福电子 湖北兴福电子材料股份有限公司 | | 道188-9号2002室 | 道188-9号2002室 | | --- | --- | --- | | 电子信箱 | ir@sinophorus.com | ir@sinophorus.com | | | | 单位:元 币种:人民币 | | | | 本报告期末比上年度末 | | | 本报告期末 | 上年度末 | | | | 增减(%) | 总资产 4,084,424,025.80 2,994,235,626.06 36.41 归属于上市公司股 东的净资产 | | | | 本报告期比上年同期增 | | --- | --- | --- | --- | | | 本报告期 | 上年同期 | | | | | | 减(%) | | 营业收入 | 672,479,150.20 | 511,658,167.02 | 31.43 | | 利润总额 | 117,568,592.62 | 94,889,137.00 | 23.90 | | 归属于上市公司股 | | | | | 东的净利润 | | ...
苑东生物: 苑东生物:2025年半年度报告摘要
Zheng Quan Zhi Xing· 2025-08-18 11:14
成都苑东生物制药股份有限公司2025 年半年度报告摘要 公司代码:688513 公司简称:苑东生物 成都苑东生物制药股份有限公司 成都苑东生物制药股份有限公司2025 年半年度报告摘要 第一节 重要提示 规划,投资者应当到 http://www.sse.com.cn 网站仔细阅读半年度报告全文。 公司已在本报告中详细阐述公司在生产经营过程中可能面临的各种风险及应对措施,敬请查 阅第三节"管理层讨论与分析"之"四、风险因素"。敬请投资者予以关注,注意投资风险。 完整性,不存在虚假记载、误导性陈述或重大遗漏,并承担个别和连带的法律责任。 无 □适用 √不适用 第二节 公司基本情况 公司股票简况 公司股票简况 股票种类 股票上市交易所 股票简称 股票代码 变更前股票简称 上海证券交易所科 A股 苑东生物 688513 不适用 创板 公司存托凭证简况 □适用 √不适用 联系人和联系方式 联系人和联系方式 董事会秘书 证券事务代表 姓名 李淑云 张敏 电话 028-86106668 028-86106668 办公地址 成都市双流区安康路8号 成都市双流区安康路8号 电子信箱 ydsw@eastonpharma.cn y ...